3.28

4.93% -0.17

After Hours: 3.28

Xeris Biopharma Holdings Inc (XERS)

Overview News Price History Option Chain Financials Discussions Forecast

Xeris Biopharma Holdings Inc stock is traded at $3.28, with a volume of 877.93K. It is down -4.93% in the last 24 hours and up +1.55% over the past month. Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.

Previous Close:

$3.45

Open:

$3.47

24h Volume:

877.93K

Relative Volume:

0.57

Market Cap:

$488.99M

Revenue:

$181.41M

Net Income/Loss:

$-59.56M

P/E Ratio:

-6.3077

EPS:

-0.52

Net Cash Flow:

$-38.83M

1W Performance:

+6.15%

1M Performance:

+1.55%

6M Performance:

+69.95%

1Y Performance:

+77.78%

1-Day Range:

$3.28

$3.47

1-Week Range:

$3.05

$3.52

52-Week Range:

$1.69

$3.64

Xeris Biopharma Holdings Inc Stock (XERS) Company Profile

Name

Xeris Biopharma Holdings Inc

Sector

Healthcare (1180)

Industry

Biotechnology (675)

Phone

844-445-5704

Address

1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL

Employee

377

Twitter

@XerisPharma

Next Earnings Date

2024-12-08

Latest SEC Filings

XERS's Discussions on Twitter

Compare XERS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
XERS Xeris Biopharma Holdings Inc	3.28	488.99M	181.41M	-59.56M	-38.83M	-0.42
VRTX Vertex Pharmaceuticals Inc	468.13	120.56B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	750.22	82.44B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	616.55	36.87B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	253.07	32.64B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	118.39	28.38B	3.30B	-501.07M	1.03B	-2.1146

Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-11-24	Downgrade	Piper Sandler	Overweight → Neutral
Mar-28-24	Initiated	Oppenheimer	Outperform
Aug-28-23	Initiated	Craig Hallum	Buy
Oct-21-22	Initiated	Jefferies	Buy
Apr-28-22	Initiated	Craig Hallum	Buy
Nov-17-21	Initiated	SVB Leerink	Outperform
Oct-29-21	Initiated	H.C. Wainwright	Buy
Apr-07-21	Resumed	RBC Capital Mkts	Outperform
Feb-18-20	Initiated	Piper Sandler	Overweight
Jul-16-18	Initiated	Jefferies	Buy
Jul-16-18	Initiated	Leerink Partners	Outperform
Jul-16-18	Initiated	RBC Capital Mkts	Outperform

View All

Xeris Biopharma Holdings Inc Stock (XERS) Latest News

Nov 27, 2024

XERS (Xeris Biopharma Holdings) Revenue : $187.4 Mil (TTM As of Sep. 2024) - GuruFocus.com

Nov 27, 2024

Nov 26, 2024

Xeris Biopharma Holdings (FRA:2B30) 3-Year Book Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com

Nov 26, 2024

XERS (Xeris Biopharma Holdings) Other Stockholders Equity : $0.0 Mil (As of Sep. 2024) - GuruFocus.com

Nov 26, 2024

XERS (Xeris Biopharma Holdings) EPS (Diluted) : $-0.44 (TTM As of Sep. 2024) - GuruFocus.com

Nov 26, 2024

XERS (Xeris Biopharma Holdings) GF Score : 75/100 (As of Nov. 26, 2024) - GuruFocus.com

Nov 26, 2024

XERS (Xeris Biopharma Holdings) Accounts Payable : $7.5 Mil (As of Sep. 2024) - GuruFocus.com

Nov 26, 2024

GSA Capital Partners LLP Sells 578,313 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World

Nov 26, 2024

Xeris to Participate in Piper Sandler 36th Annual Healthcare Conference - Business Wire

Nov 26, 2024

GSA Capital Partners LLP Trims Stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - MarketBeat

Nov 26, 2024

Nov 25, 2024

XERS (Xeris Biopharma Holdings) Cash-to-Debt : 0.26 (As of Sep. 2024) - GuruFocus.com

Nov 25, 2024

XERS (Xeris Biopharma Holdings) Shares Outstanding (EOP) : 149.0 Mil (As of Sep. 2024) - GuruFocus.com

Nov 25, 2024

XERS (Xeris Biopharma Holdings) Other Current Liabilities : $34.8 Mil (As of Sep. 2024) - GuruFocus.com

Nov 25, 2024

Nov 17, 2024

Analysts Expect Breakeven For Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Before Long - Yahoo Finance

Nov 17, 2024

Nov 16, 2024

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS): When Will It Breakeven? - Simply Wall St

Nov 16, 2024

Nov 14, 2024

HC Wainwright Forecasts Reduced Earnings for Xeris Biopharma - Defense World

Nov 14, 2024

Wealth Enhancement Advisory Services LLC Invests $35,000 in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World

Nov 14, 2024

FY2024 EPS Estimate for Xeris Biopharma Raised by Analyst - Defense World

Nov 14, 2024

Nov 13, 2024

HC Wainwright Forecasts Higher Earnings for Xeris Biopharma - MarketBeat

Nov 13, 2024

Xeris Biopharma (NASDAQ:XERS) Rating Lowered to Neutral at Piper Sandler - Defense World

Nov 13, 2024

Xeris Biopharma (NASDAQ:XERS) Stock Price Expected to Rise, HC Wainwright Analyst Says - Defense World

Nov 13, 2024

Nov 12, 2024

HC Wainwright Forecasts Weaker Earnings for Xeris Biopharma - MarketBeat

Nov 12, 2024

Nov 10, 2024

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 10, 2024

Nov 09, 2024

Earnings call: Xeris Biopharma posts record revenue in Q3 2024 - Investing.com India

Nov 09, 2024

Earnings call: Xeris Biopharma posts record revenue in Q3 2024 By Investing.com - Investing.com Nigeria

Nov 09, 2024